Joseph Freedman
Cardiovascular Disease · Fort Myers, FLNPI 1801061890
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $43,255 of the $54,504 with a category attached, or 79.4%. 30 manufacturers reported payments, led by Johnson & Johnson at 49.3% of the total. 2022 is the largest year on record at $26,580, more than ten times the $1,712 reported in 2019. Among cardiovascular disease clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 384 payments — averaging $141.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$27K
- AstraZeneca$10K
- Boehringer Ingelheim$8K
- Cvrx, Inc.$5K
- Lilly USA, LLC$2K
- Amgen$734
- plus $2K from 24 others
Across 9 payments — averaging $677.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cvrx, Inc.$6K
What the payments were for
- Consulting fees$4,0507%
- Speaking & faculty fees$43,25579%
- Food & beverage$7,10913%
- Education$900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 98 | $26,888 |
| AstraZeneca | 41 | $9,616 |
| Boehringer Ingelheim | 37 | $8,105 |
| Cvrx, Inc. | 22 | $4,744 |
| Lilly USA, LLC | 3 | $1,980 |
| Amgen | 45 | $734 |
| Sanofi-aventis U.S. LLC | 16 | $332 |
| Kowa Pharmaceuticals America, Inc. | 19 | $270 |
| Novartis | 15 | $258 |
| Amarin Pharma, Inc. | 14 | $235 |
| Boston Scientific | 9 | $162 |
| Pfizer | 10 | $161 |
| Venclose Inc. | 1 | $156 |
| E.r. Squibb & Sons, L.L.C. | 11 | $150 |
| Actelion Pharmaceuticals US, Inc. | 10 | $147 |
| Abbott | 5 | $86 |
| Regeneron Healthcare Solutions, Inc. | 5 | $76 |
| Medtronic(2 entities) | 4 | $68 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $52 |
| Merck | 2 | $41 |
| Alnylam Pharmaceuticals Inc. | 2 | $40 |
| Medicure Pharma Inc. | 2 | $40 |
| Novo Nordisk | 2 | $33 |
| Amryt Pharma Holdings Ltd | 2 | $28 |
| Heartflow, Inc. | 1 | $27 |
| Biocompatibles, Inc. | 1 | $25 |
| Astellas Pharma US Inc | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Bayer | 1 | $13 |
| Elutia, Inc. | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$25,739
- JARDIANCE$9,379
- FARXIGA$9,258
- Barostim Neo System$4,431
- EVRSF$156
How this compares
$54,504 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Fort Myers
- Malissa WoodFort Myers$250K
- Michael LipinskiFort Myers$247K
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.